PP
TARS icon

PDT Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

PDT Partners’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.03M Sell
32,292
-30,734
-49% -$1.96M 0.11% 237
2026
Q1 		$4.42M Hold
63,026
– – 0.26% 123
2025
Q4 		$5.16M Hold
63,026
– – 0.33% 94
2025
Q3 		$3.75M Hold
63,026
– – 0.24% 152
2025
Q2 		$2.55M Buy
+63,026
New +$2.84M 0.14% 246

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PDT Partners's TARS Position: Q2 2026 in Review

PDT Partners reduced its Tarsus Pharmaceuticals (TARS) stake by 49% in Q2 2026, selling an estimated $1.96M and leaving 32,292 shares worth $2.03M. The position accounts for 0.11% of the portfolio, ranked #237.

PDT Partners first reported a position in TARS in Q2 2025 and has held it in 5 quarters since. The position peaked at $5.16M in Q4 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • PDT Partners held 32,292 shares of Tarsus Pharmaceuticals worth $2.03M as of Q2 2026.
  • PDT Partners sold 30,734 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.96M.
  • Tarsus Pharmaceuticals made up 0.11% of PDT Partners's portfolio in Q2 2026, its #237 holding.
  • PDT Partners first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • PDT Partners's Tarsus Pharmaceuticals position peaked at $5.16M in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.